Clinical trials: Ondansetron
Healthy
Fasting Study of Ondansetron Orally Disintegrating Tablets 8 mg to Zofran ODT® Tablets 8 mg
The objective of this study was to investigate the bioequivalence of Mylan's ondansetron orally disintegrating 8 mg tablets to GlaxoSmithKline's Zofran ODT® 8 mg tablets following a single, oral 8 mg (1 x 8 mg) dose administered…
- Trial name
- NCT00649363
- Testing
- Ondansetron Orally Disintegrating Tablets 8 mg, Zofran ODT® Tablets 8 mg
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Mylan Pharmaceuticals Inc
Healthy
Ondansetron HCl Orally Disintegrating Tablets Under Non-Fasting Conditions
The objective of this study was to compare the relative bioavailability of the test formulation of Ondansetron HCl with the already marketed reference formulation Zofran® ODT under non-fasting conditions in healthy, non-smoking…
- Trial name
- NCT00934921
- Testing
- Ondansetron, Zofran®
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Teva Pharmaceuticals USA
Schizophrenia
Evaluation of TAK-058 and Ondansetron on P50 Auditory Gating in Participants With Stable Schizophrenia
The purpose of this study is to determine whether improvement in P50 (a pharmacodynamic marker) in auditory sensory gating is demonstrated after administration of TAK-058 and ondansetron compared to placebo in participants with…
- Trial name
- NCT02614586
- Testing
- TAK-058, Ondansetron
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Takeda
Postoperative Nausea and Vomiting, Nausea and Vomiting, Postoperative
Study Of An NK-1 Anti-Emetic Medication For The Prevention Of Post-Operative Nausea And Vomiting In Female Patients
The purpose of this study is to determine the effectiveness of this medication in preventing nausea and vomiting in female patients at risk for post-operative nausea and vomiting (PONV).
- Trial name
- NCT00600990
- Testing
- GW597599
- Where
- 55 sites in United States, Australia and 10 more
- Volunteers
- 624 people
- Sponsor
- GlaxoSmithKline
Nausea and Vomiting Chemotherapy-Induced, Nausea Post Chemotherapy
Study With IV NEPA (Fosnetupitant/Palonosetron) for the Prevention of Chemotherapy-induced Nausea and Vomiting in Paediatric Cancer Patients Undergoing Highly Emetogenic Chemotherapy (HEC)
Chemotherapy often causes nausea and vomiting (CINV), and this is a major problem for the children being treated for cancer. To prevent this, a combination of two substances in fixed proportion (IV NEPA) was developed.
- Trial name
- NCT06904235
- Testing
- IV NEPA (fosnetupitant/palonosetron), Reference Treatment: IV ondansetron infusion, Reference Treatment: IV fosaprepitant infusion
- Where
- 20 sites in Greece, Poland and 2 more
- Volunteers
- 95 people
- Sponsor
- Helsinn Healthcare SA
Nausea, Vomiting
An Investigational Drug for the Prevention of Chemotherapy-Induced Nausea and Vomiting (MK-0869-071)
This protocol will study an investigational drug treatment plan against standard therapy in the prevention of chemotherapy-induced nausea and vomiting in patients diagnosed with breast cancer who are to be treated with up to 4…
- Conditions
- Nausea, Vomiting, Breast Neoplasms
- Trial name
- NCT00092183
- Testing
- MK0869, aprepitant / Duration of Treatment: 3 days, Comparator: ondansetron / Duration of Treatment: 3 days
- Volunteers
- 866 people
- Sponsor
- Merck Sharp & Dohme LLC
Solid Tumors
AZD1775 Continued Access Study to Assess Safety and Tolerability for Patients Enrolled in AZD1775 Clinical Pharmacology Studies
Open-label, non-randomised study to provide continued access to AZD1775 for patients with advanced solid tumours who have previously completed an AZD1775 clinical pharmacology study and to investigate the safety of AZD1775.
- Trial name
- NCT03313557
- Testing
- Wee-1 kinase inhibitor AZD1775
- Where
- 14 sites in United States, France and 2 more
- Volunteers
- 48 people
- Sponsor
- AstraZeneca
Nausea
Bioavailability Study of Anti Nausea Medication With and Without Food (EUR-1025)
This study is to assess the effect of food on a single dose of Ondansetron when taken with a meal on an empty stomach.
- Trial name
- ODO-P8-689 (NCT00981487)
- Testing
- Ondansetron
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Forest Laboratories
Nausea and Vomiting, Postoperative, Postoperative Nausea and Vomiting
Casopitant And ZOFRAN To Prevent Post Operative Nausea And Vomiting In Women
This study is being conducted to see if adding GW679769 (casopitant) to ZOFRAN will significantly decrease the number of patients who experience nausea and vomiting after surgery.
- Trial name
- NCT00334152
- Testing
- casopitant
- Where
- 70 sites in United States, Belgium and 9 more
- Volunteers
- 515 people
- Sponsor
- GlaxoSmithKline
Nausea, Vomiting
To Demonstrate the Relative Bioavailability Study of Ondansetron HCl 24 mg Tablets Under Non-Fasting Conditions
To demonstrate the relative bioavailability study of Ondansetron HCl 24 mg tablets under non-fasting conditions.
- Trial name
- NCT00947128
- Testing
- Ondansetron HCl 24 mg Tablets (Sandoz, Inc.), Zofran (Ondansetron HCl) 24 mg Tablets (GlaxoSmithKline)
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Sandoz
Postoperative Nausea and Vomiting
A Randomized Controlled Study of Rolapitant for the Prevention of Nausea and Vomiting Following Surgery (Study P04937AM1)(COMPLETED)
This is a multicenter, randomized, controlled study in women who are having elective open abdominal surgery with general anesthesia and who are expected to need patient-controlled analgesia (PCA) after surgery.
- Trial name
- NCT00539721
- Testing
- Rolapitant Dose 1, Rolapitant Dose 2, Rolapitant Dose 3
- Volunteers
- 619 people
- Sponsor
- Merck Sharp & Dohme LLC
Healthy
Two Way Bioequivalence Study Under Fed Conditions
The purpose of this study is to assess the single dose bioequivalence of Ondansetron ODFS 8mg with Zofran ODT® (Containing Ondansetron 8 mg) in healthy, male and female adult, human study participants under fed conditions.
- Trial name
- NCT01217801
- Testing
- Ondansetron (ODFS), Ondansetron (ODT)
- Where
- India
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- MonoSol Rx
Chemotherapy Induced Nausea and Vomiting
Dronabinol Versus Standard Ondansetron Antiemetic Therapy in Preventing Delayed-Onset Chemotherapy-Induced Nausea and Vomiting
The primary purpose of the study is to determine the efficacy of oral dronabinol versus standard ondansetron antiemetic therapy in preventing delayed-onset chemotherapy-induced nausea and vomiting (CINV) or retching by measuring…
- Trial name
- NCT00642512
- Testing
- dronabinol, ondansetron, dronabinol/ondansetron
- Where
- 43 sites in United States
- Volunteers
- 64 people
- Sponsor
- Solvay Pharmaceuticals
Healthy
Fasting Study of Ondansetron Tablets 24 mg and Zofran® Tablets 24 mg
The objective of this study was to investigate the bioequivalence of Mylan's ondansetron 24 mg tablets to GSK's Zofran® 24 mg tablets following a single, oral 24 mg (1 x 24 mg) dose administered under fasting conditions.
- Trial name
- NCT00649532
- Testing
- Ondansetron Tablets 24 mg, Zofran® Tablets 24 mg
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Mylan Pharmaceuticals Inc
Chemotherapy-induced Nausea and Vomiting
Oral Akynzeo® vs Standard of Care in Preventing CINV in High-risk MEC Patients (MyRisk)
MyRisk: Efficacy and safety evaluation of oral Akynzeo® in patients receiving MEC at high risk of developing CINV based on a prediction tool. A multinational and multicenter study.
- Trial name
- CINV (NCT04817189)
- Testing
- NEPA (300mg netupitant/0.5mg palonosetron), Granisetron, 2 mg (oral) or 1 mg (IV) OR Palonosetron, 0.5 mg (oral), 0.25mg (IV) OR Ondansetron, 16 mg (oral) or 8 mg (IV) OR Dolasetron 100 mg (oral) OR Tropisetron 5 mg (oral or IV), Dexamethasone, 8 mg (oral) or equivalent IV dose
- Where
- 19 sites in China, Czechia and 5 more
- Volunteers
- 414 people
- Sponsor
- Helsinn Healthcare SA
Neuroendocrine Tumors
Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETs
The purpose of this clinical phase I/II study was to investigate the safety and tolerability of satoreotide tetraxetan (177Lu-IPN01072, formerly known as 177Lu-OPS201) used for the treatment of patients with neuroendocrine tumors…
- Trial name
- NCT02592707
- Testing
- Satoreotide tetraxetan, Amino acid solution, Antiemetic
- Where
- 9 sites in United States, Australia and 6 more
- Volunteers
- 40 people
- Sponsor
- Ipsen
Nausea and Vomiting, Chemotherapy-Induced
A Study of the Drug Casopitant for the Prevention of Nausea Caused By Cisplatin-Based Highly Emetogenic Chemotherapy
This is a Phase III trial designed to demonstrate that casopitant when added to dexamethasone and ondansetron is more effective in the prevention of vomiting then dexamethasone and ondansetron alone, in patients who receive a…
- Trial name
- NCT00431236
- Testing
- Oral Casopitant (GW679769), IV Casopitant (GW679769), IV ondansetron hydrochloride
- Where
- 80 sites in Argentina, Belgium and 20 more
- Volunteers
- 810 people
- Sponsor
- GlaxoSmithKline
Body Contouring
Evaluation of Procedural Analgesia for Liposonix Treatment
The objectives of this study are to evaluate the safety and effectiveness of procedural analgesia for improvements in tolerability of treatment with the Liposonix System.
- Trial name
- NCT01993238
- Testing
- Liposonix System (Model 2), Pre-treatment analgesia
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Solta Medical
Chemotherapy-Induced Nausea and Vomiting
Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)(0869-130)(COMPLETED)
The study will test aprepitant for the prevention of CINV in patients receiving their initial cycle of Moderately Emetogenic Chemotherapy (MEC).
- Trial name
- NCT00337727
- Testing
- aprepitant, Comparator: ondansetron, Comparator: dexamethasone
- Volunteers
- 848 people
- Sponsor
- Merck Sharp & Dohme LLC
Preventing of Postoperative Nausea and Vomiting in Adults
A Trial of HRS5580 in Prevention of Postoperative Nausea and Vomiting of Adults
The study is being conducted to evaluate the efficacy, and safety of HRS5580 for preventing of postoperative nausea and vomiting in adults. To explore the reasonable dosage of HRS5580 for postoperative nausea and vomiting.
- Trial name
- NCT06475846
- Testing
- HRS5580, Ondansetron, blank preparation
- Where
- 2 sites in China
- Volunteers
- 235 people
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.